维普中文期刊产品整合服务
87篇 您的检索式:作者名="Pharmd"
    题名 作者 年代 出处 被引量
1卫生技术评估:全球经验综述显示文摘一、《健康价值》特刊中的卫生技术评估综述近来,在药物发展和卫生管理领域中,卫生技术评估(Health Technology Assessment,HTA)引发了较多的关注和争议。这是由于HTA带来的高风险收益引起了人们的兴趣。对HTA结果的理解很大程度上取决于各主体的视角。评论家认为,目前HTA的应用还仅限于对新医疗技术进行评估以设置其使用上的限制,但更应提倡运用HTA技术达到促进资源的有效配置及改善群体健康的目的。John C.O'Donnell PhD Sissi V.Pham PharmD Chris L.Pashos DavidW.Miller Marilyn Dix Smith BPharm 刘庆婧 吴晶 2010中国药物经济学2010,,1:4
2卡尼汀(肉毒碱)在儿科肠外营养和全营养混合液中的稳定性显示文摘长链脂肪酸进入线粒体进行氧化供能时需要卡尼汀参与,他是儿科肠外营养病人的条件必需营养素。根据我们以前的临床研究结果,推荐卡尼汀的剂量为20mg·kg-1·d-1。然而,肠外营养和全营养混合液中卡尼汀的稳定性尚未得以正确评估。在儿童肠外营养和全营养混合液中以130~200mg/L的标准加以卡尼汀,所配混合液中卡尼汀稳定性的测定时间分别为:配制后的当时和配制后的第1天、第7天、第15天和第30天(此间在4~5℃中保存)。测定后的制剂则置室温保存,并用荧光灯持续照射,分别在0、6、12、18和24小时采取标本。用碳14放射分析技术重复测定同一标本的卡尼汀浓度,这是稳定性的标志。同时检测混合液的pH值变化、颜色变化和可见沉淀物的发生。结果表明:保存30天的混合液,没有pH值和颜色的变化,也没有可见沉淀的发生。在配制后当时,6个不同标本的卡尼汀回收率为93.9%±5.31%(理论值的均数±标准差,区间为87.8%~101%)。4~5℃存放的标本,在不同时间点所测定的结果相近。存放30天后,再室温放置24小时,卡尼汀的理论回收率为93.3%±7.30%(区间为81.0%~102%)。半胱氨酸和雷尼替丁都不影响卡尼汀的稳定性。我们进行包括经Y型管输往20%脂肪乳的模拟输液试验,经24小时的输注之后,M.C.Storm PhD B.Wang MD R.A.Helras PharmD 牛玉坚 2000中国临床营养杂志2000,8,1:2
3Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma显示文摘Perry Shen MD Jason Hawksworth MD James Lovato PhD Brian W. Loggie MD Kim R. Geisinger MD Ronald A. Fleming PharmD Edward A. Levine MD 2004Annals of Surgical Oncology2004,,2:2
4Telbivudine for the management of chronic hepatitis B virus infection显示文摘MATIHEWS SJ PHARMD RPH 2007Clin Ther2007,29,26:1
5US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey显示文摘David R Strutton Jonathan W Kowalski PharmD Dee Anna Glaser Paul E Stang 2004Journal of the American Academy of Dermatology2004,,2:1
6Tissue repair,contraction,and the myofibroblast显示文摘PharmD AD Chaponnier C Gabbiani G 2005Wound Repair Re-gen2005,13,1:1
7Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins inthe Prefrontal Cortex of Pateints With Bipolar Disorder 显示文摘Ana C Andreazza PharmD Li Shao 2010Arch Gen Psychiatry2010,67,4:1
8Prevalence of inadequate glyeemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002显示文摘Fox K M Gerber Pharmd R A Bolinder B 2006Clin Ther2006,28,3:1
9US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey显示文摘David R Strutton Jonathan W Kowalski PharmD Dee Anna Glaser Paul E Stang 2004Journal of the American Academy of Dermatology2004,,2:1
10Prevalence of inade- quate glycemiccontrol among patients with type 2 diaberes in the U- nited Kingdom general practice research database: series of retro- spective Analysis of data from 1998 through 2002 显示文摘Fox KM Gerber Pharmd RA BolinderB 2006Clin Ther2006,28,3:1
11Clinical pharmacokinelics of sotalod 显示文摘James J Hanyok Pharmd 1993The American Journal of Cardiology1993,72,:1
12Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis 显示文摘Stefan Vegter PharmD Keith Tolley MPhil 2011Value in Health2011,14,:1
13Development and Evolution of a Primary Care - Based Diabetes Disease Management Program 显示文摘Malone R Shilliday BB PharmD 2007Clinical Diabetes2007,25,1:1
14Valproate-mediated disturbances of hemostasis : relationship to dose and plasma concentrationl显示文摘Pharmd BG Spencer MD Maly HN 1994Neurology1994,44,4:1
15右旋美托咪啶-咪达唑仑与丙泊酚用于小儿磁共振检查中麻醉维持的比较显示文摘背景右旋美托咪啶是一种仪,受体激动剂,目前正在研究其是否适合用于小儿麻醉。本研究旨在比较右旋美托咪啶一咪达唑仑与丙泊酚对于七氟烷麻醉儿童磁共振扫描(M对)中的药效学反应差异。方法40例1~10岁,ASA1或2级,拟行MRI检查的患儿,随机分为2组,两组均用七氟烷诱导,一组以右旋美托咪啶.咪达唑仑维持麻醉,另一组以丙泊酚维持麻醉。右旋美托咪啶组先静注负荷量(1μg/kg)后持续泵入(0.5μg·kg^-1·h^-1)。开始泵注后静注咪达唑仑(0.1mg/kg)。丙泊酚持续泵入(250—300μg·kg^-1·min^-1)。由一名不了解麻醉方案的护士来记录复苏时间及血流动力学变化。结果右旋美托咪啶组手术后完全恢复及出院时间明显长于(约15分钟)丙泊酚组。与丙泊酚组比较,右旋美托咪啶组心率减慢,收缩压增高。两组呼吸系统指标相近。恢复过程中,两组血流动力学反应相近。在麻醉及手术后恢复过程中,心肺指标均在同年龄段儿童的正常范围内。无麻醉意外发生。结论在MRI检查中,右旋美托咪啶.咪达唑仑提供足够的麻醉深度,但-I丙泊酚相比麻醉复苏时间稍长。与丙泊酚组比较,使用右旋美托咪啶的患儿心率慢、收缩压高。两种方式的呼吸系统指标相近。Christopher Heard, MBChB, FRCA Frederick Burrows, MD Kristin Johnson, PharmD Prashant Joshi, MD James Houck, MD Jerrold Lerman FRCPC, FANZCA 马敏(译) 江海星(译) 饶艳(校) 王焱林(校) 2010麻醉与镇痛2010,,2:1
16Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database:A series of retrospective analyses of data from 1998 through 2002显示文摘Fox KM Gerber Pharmd RA Bolinder B 0,,03:1
17Surgery After Downstaging of Unresectable Hepatic Tumors With Intra-Arterial Chemotherapy显示文摘Funda Meric MD Yehuda Z. Patt MD Steve A. Curley MD Judy Chase PharmD Mark S. Roh MD J. Nicolas Vauthey MD Lee M. Ellis MD 2000Annals of Surgical Oncology2000,,7:1
18A Randomized Trial of Calcium Supplementation for Childhood Lead Poisoning 显示文摘Morri E Markowitz MD Mark Sinnett PharmD John F & Rosen MD 2004PEDIATRICS2004,113,2:1
19Renal cell carcinoma: diagnosis and treatment, 1994-2003 显示文摘Hutson T E Pharmd D 2005Proc(Bayl Univ Med Cent)2005,18,:1
20Nuclear factor kappa B:important transcription factor and therapeutic target显示文摘Lee JIK Pharmd D Gilbert J 1998J Clin Pharmacol1998,38,:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费